Literature DB >> 32300496

Coronavirus Disease: A Review of a New Threat to Public Health.

Kamleshun Ramphul1, Stephanie G Mejias2.   

Abstract

In December 2019, several patients from Wuhan, China were admitted to hospitals with symptoms of pneumonia. As the number of patients presenting with similar symptoms started to rise, the causative agent was eventually isolated from samples. It was initially called the 2019 novel coronavirus (2019-nCoV) and has been recently relabelled as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); the disease it causes has been named coronavirus disease 2019 (COVID-19). Over the next few weeks, the virus spread from Wuhan to affect different provinces in China and, after a few months, it is now present in 109 countries. As of March 10, 2020, there have been 113,702 confirmed cases globally, and 4,012 deaths have been registered. The World Health Organization (WHO) called COVID-19 a pandemic on March 11, 2020. There are multiple drug trials going on with some positive results. However, since no vaccine is available, the best way to combat the virus is by preventive methods.
Copyright © 2020, Ramphul et al.

Entities:  

Keywords:  coronavirus disease; covid-19; sars-cov-2; severe acute respiratory syndrome coronavirus 2; wuhan

Year:  2020        PMID: 32300496      PMCID: PMC7158591          DOI: 10.7759/cureus.7276

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


Introduction and background

Over the last few decades, the world has seen the existence of new viruses that posed serious threats to global health. In late December 2019, several patients in Wuhan, China started reporting symptoms that resembled pneumonia. A new virus was identified and initially called the 2019 novel coronavirus (2019-nCoV). The World Health Organization (WHO) eventually changed the name of the virus to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. The disease it causes has been named coronavirus disease 2019 (COVID-19). The SARS-CoV is a positive-stranded RNA virus that originates from the Coronaviridae family. Other viruses from the same family include the severe acute respiratory syndrome coronavirus (SARS-CoV), which appeared in 2002, and Middle East respiratory syndrome coronavirus (MERS-CoV), which was reported in 2012 [2]. Since the virus is spreading worldwide, on March 11, 2020, the WHO officially described the COVID-19 outbreak as a pandemic.

Review

Epidemiology As of March 10, 2020, the WHO has reported that there are 113,702 confirmed cases globally, and 4012 deaths have been registered; 71% of all confirmed cases (80,924) and 78% of all deaths related to COVID-19 (3140) are from China and its territories. Since the first reported case in Wuhan, 109 other countries have declared that they have at least one confirmed case of COVID-19. The WHO has officially classified China as a “very high risk” region for COVID-19 [3]. Mainland China and territories The province of Hubei, which includes Wuhan, currently has the highest confirmed number of cases and deaths in mainland China (67,760 cases and 3,024 deaths). Among the regions in China that have crossed the four-digit mark, Guangdong, Henan, Zhejiang, and Hunan each have 1,353, 1,272, 1,215, and 1,018 cases, respectively (Table 1). The second-highest number of deaths was reported in Guangdong with 22 cases.
Table 1

Number of confirmed cases and deaths linked with COVID-19 in China as of March 10, 2020 (reported by the WHO)

SAR: special administrative region; WHO: World Health Organization

Province Confirmed cases Deaths
Hubei67,7603,024
Guangdong1,3538
Henan1,27222
Zhejiang1,2151
Hunan1,0184
Anhui9906
Jiangxi9351
Shandong7586
Jiangsu6310
Chongqing5766
Sichuan5393
Heilongjiang48113
Beijing4298
Shanghai3423
Hebei3186
Fujian2961
Guangxi2522
Shaanxi2451
Yunnan1742
Hainan1686
Guizhou1462
Tianjin1363
Shanxi1330
Liaoning1251
Gansu1242
Hong Kong SAR1153
Jilin931
Xinjiang763
Ningxia750
Inner Mongolia751
Taipei and environs451
Qinghai180
Macao SAR100
Xizang10
Total80,9243,140

Number of confirmed cases and deaths linked with COVID-19 in China as of March 10, 2020 (reported by the WHO)

SAR: special administrative region; WHO: World Health Organization Outside China While South Korea and Iran were initially the two most affected countries outside China, the number of cases started to rise in Italy in late February and, as of March 10, 2020, Italy is the country outside China with the highest number of total confirmed cases (9,172) (Table 2).
Table 2

Number of confirmed cases and deaths related to COVID-19 outside of China as of March 10, 2020 (reported by the WHO)

WHO: World Health Organization

CountryNumber of confirmed casesDeaths
South Korea7,51354
Japan5149
Italy9,172463
France1,40230
Germany1,1382
Spain1,02428
Iran7,161237
USA47219
Other countries (excluding China)3,68623

Number of confirmed cases and deaths related to COVID-19 outside of China as of March 10, 2020 (reported by the WHO)

WHO: World Health Organization What is severe acute respiratory syndrome coronavirus 2? SARS-CoV-2 is a positive-sense, single-stranded RNA virus. The SARS-CoV-2 virion is about 50-200 nm in diameter and consists of four main structural proteins; spike (S), envelope (E), membrane (M), and nucleocapsid (N) [4]. The S protein allows the virus to bind to the host’s cell membrane. The angiotensin-converting enzyme 2 (ACE2) receptors on host cells have been found to be the target of S proteins. It then undergoes structural changes to fuse with the host, and this eventually allows viral genes to enter the host cell [5-7]. Genomic comparison has shown that the SARS-CoV-2 has an 80% resemblance to Rhinolophus sinicus bat and 96% resemblance with the Rhinolophus affinis bat [8,9]. One research team found that one sample of the virus had a 99% genomic similarity with pangolins and suggested that the animal may be an intermediate host to the virus [10,11]. According to the Centers for Disease Control and Prevention (CDC), the transmission of SARS-CoV-2 occurs mostly person-to-person via respiratory droplets within a range of 180 cm. The virus can also be transmitted if a person touches a mucosal surface after touching an object with the virus on it [12]. What are the clinical symptoms of COVID-19? While the incubation period of the virus was initially thought to be 14 days, multiple cases have been reported with shorter timelines. A study by Guan et al. calculated the median incubation period to be four days with a lower interquartile range of two days and an upper interquartile range of seven days. In their study, the most common finding on imaging was ground-glass opacity on CT (56.4%) [13]. They found that 43.8% had a fever on admission and 88.7% during hospitalization. The cough was also a common symptom and was seen in 67.8% of patients. The Chinese Center for Disease Control and Prevention has reported that 87% of confirmed cases were in adults aged between 30 and 79 years. The mortality and case fatality rate increased with increasing ages; the case fatality rate was 8% in patients aged between 70 and 79 years while it was 15% in those aged 80 years or more [14]. A study involving 10 children showed that most presented with fever (80%) while 60% had cough [15]. All children presented with mild symptoms and they all recovered. The study also reported that the patients had prolonged virus shedding in the respiratory tract and feces, even during their convalescent stage. A second study involved nine infected infants aged 1-11 months. Four out of the nine patients presented with fever; one infant had no symptoms but was tested positive for the virus. None of the infants needed mechanical ventilation or had to be admitted in intensive care [16]. How are patients tested for SARS-CoV-2? Samples from the upper respiratory tract are used to test for the virus. Polymerase chain reaction (PCR) is used to identify their viral RNA. If the test is positive, the diagnosis of SARS-CoV-2 is confirmed. Negative tests with a strong suspicion, such as clinical symptoms or exposure, can be repeated using samples from other respiratory sites [17,18]. Treatment of COVID-19 Multiple antiviral regimens are being tried to help patients with severe symptoms of the virus. Lopinavir and ritonavir have been used in some clinical trials. Lim et al. reported that the drugs helped their patient as he improved clinically and viral loads decreased significantly [19]. Four COVID-19 patients were recruited by Wang et al. for a study in Shanghai, China, and they also improved with a combined therapy of lopinavir and ritonavir [20]. In Singapore, confirmed cases that were hospitalized were also given the combined antiviral therapy of lopinavir and ritonavir. While some patients reported improvement in their symptoms, four patients developed nausea, vomiting, or diarrhea, and three patients showed elevated liver function test results [21]. Several other treatment options such as Remdesivir (Gilead Sciences, Foster City, CA), peptide (EK1), neuraminidase inhibitors, chloroquine, and arbidol have also been suggested [22]. There are multiple research teams trying to investigate a possible vaccine for the virus. The role of the spike protein in the viral infectivity and pathogenesis is a possible preventive target [23]. How to prevent COVID-19? The CDC recommends multiple steps to prevent the transmission and risk of SARS-CoV-2. Frequent hand washing lasting at least 20 seconds by using soap and water is advised. Hand sanitizers with at least 60% alcohol can also be used as an alternative. The public has also been told to avoid touching mucosal surfaces such as the mouth and the nose with hands that have not been washed. Anyone showing symptoms of the virus should try to seek appropriate medical help. They should also limit their exposure to other unaffected people and cover their noses and mouths when coughing or sneezing. They are also advised to wear a facemask if they present with symptoms. Frequent disinfection and cleaning are advised for groups that are at risk of contracting the virus [24].

Conclusions

The SARS-CoV-2 is spreading across the world at an alarming rate. The elderly and immunocompromised patients are most vulnerable to the mortal repercussions of the virus. While some treatment protocols have shown some promise, there is at present no confirmed cure for the virus and no vaccine has been developed. With proper preventive measures, the virus can be contained and the population protected.
  14 in total

1.  Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China.

Authors:  Min Wei; Jingping Yuan; Yu Liu; Tao Fu; Xue Yu; Zhi-Jiang Zhang
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

2.  Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.

Authors:  Zhenwei Wang; Xiaorong Chen; Yunfei Lu; Feifei Chen; Wei Zhang
Journal:  Biosci Trends       Date:  2020-02-09       Impact factor: 2.400

3.  Drug treatment options for the 2019-new coronavirus (2019-nCoV).

Authors:  Hongzhou Lu
Journal:  Biosci Trends       Date:  2020-01-28       Impact factor: 2.400

4.  Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.

Authors:  Barnaby Edward Young; Sean Wei Xiang Ong; Shirin Kalimuddin; Jenny G Low; Seow Yen Tan; Jiashen Loh; Oon-Tek Ng; Kalisvar Marimuthu; Li Wei Ang; Tze Minn Mak; Sok Kiang Lau; Danielle E Anderson; Kian Sing Chan; Thean Yen Tan; Tong Yong Ng; Lin Cui; Zubaidah Said; Lalitha Kurupatham; Mark I-Cheng Chen; Monica Chan; Shawn Vasoo; Lin-Fa Wang; Boon Huan Tan; Raymond Tzer Pin Lin; Vernon Jian Ming Lee; Yee-Sin Leo; David Chien Lye
Journal:  JAMA       Date:  2020-04-21       Impact factor: 56.272

5.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

Review 6.  Transmission routes of 2019-nCoV and controls in dental practice.

Authors:  Xian Peng; Xin Xu; Yuqing Li; Lei Cheng; Xuedong Zhou; Biao Ren
Journal:  Int J Oral Sci       Date:  2020-03-03       Impact factor: 6.344

7.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

8.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

9.  Persons Evaluated for 2019 Novel Coronavirus - United States, January 2020.

Authors:  Kristina L Bajema; Alexandra M Oster; Olivia L McGovern; Stephen Lindstrom; Mark R Stenger; Tara C Anderson; Cheryl Isenhour; Kevin R Clarke; Mary E Evans; Victoria T Chu; Holly M Biggs; Hannah L Kirking; Susan I Gerber; Aron J Hall; Alicia M Fry; Sara E Oliver
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-02-14       Impact factor: 17.586

10.  A Case Series of Children With 2019 Novel Coronavirus Infection: Clinical and Epidemiological Features.

Authors:  Cai Jiehao; Xu Jin; Lin Daojiong; Yang Zhi; Xu Lei; Qu Zhenghai; Zhang Yuehua; Zhang Hua; Jia Ran; Liu Pengcheng; Wang Xiangshi; Ge Yanling; Xia Aimei; Tian He; Chang Hailing; Wang Chuning; Li Jingjing; Wang Jianshe; Zeng Mei
Journal:  Clin Infect Dis       Date:  2020-09-12       Impact factor: 9.079

View more
  14 in total

Review 1.  COVID-19 pandemic crisis-a complete outline of SARS-CoV-2.

Authors:  Sana Saffiruddin Shaikh; Anooja P Jose; Disha Anil Nerkar; Midhuna Vijaykumar Kv; Saquib Khaleel Shaikh
Journal:  Futur J Pharm Sci       Date:  2020-11-17

2.  Clinical Characteristics of 195 Cases of COVID-19 with Gastrointestinal Symptoms COVID-19 with Gastrointestinal Symptoms.

Authors:  Ting Zhan; Yalin Tang; Zheng Han; Qingxi Zhu; Jie Tan; Meng Liu; Yisan Cai; Min Huang; Xiaoli Chen; Xueting Cheng; Junsheng Deng; Xiaodong Huang; Xia Tian
Journal:  Turk J Gastroenterol       Date:  2021-02       Impact factor: 1.852

3.  Hypertension, diabetes mellitus, and cerebrovascular disease predispose to a more severe outcome of COVID-19.

Authors:  Kamleshun Ramphul; Petras Lohana; Yogeshwaree Ramphul; Yun Park; Stephanie Mejias; Balkiranjit Kaur Dhillon; Shaheen Sombans; Renuka Verma
Journal:  Arch Med Sci Atheroscler Dis       Date:  2021-04-12

Review 4.  Nigeria and Italy Divergences in Coronavirus Experience: Impact of Population Density.

Authors:  Emmanuel O Amoo; Olujide Adekeye; Adebanke Olawole-Isaac; Fagbeminiyi Fasina; Paul O Adekola; Gbemisola W Samuel; Moses A Akanbi; Muyiwa Oladosun; Dominic E Azuh
Journal:  ScientificWorldJournal       Date:  2020-05-21

Review 5.  The novel coronavirus and challenges for general and paediatric dentists.

Authors:  Vishwendra Singh; Gurvanit K Lehl; Manjit Talwar; Ankur Luthra
Journal:  Occup Med (Lond)       Date:  2020-07-17       Impact factor: 1.611

6.  Knowledge and Perception of COVID-19 among Pedodontists in India: A Quick Online Cross-sectional Study.

Authors:  Arunkumar Sajjanar; Nilesh Rojekar; Niharika Gahlod; Harshita Shukla; Durga Bhattad; Jayshree Sajjanar
Journal:  Int J Clin Pediatr Dent       Date:  2020

7.  A Preventive and Control Strategy for COVID-19 Infection: An Experience From a Third-Tier Chinese City.

Authors:  Shushan Fan; Min Wu; Shengjun Ma; Shouguo Zhao
Journal:  Front Public Health       Date:  2020-10-15

Review 8.  Management of Coronavirus Disease 2019 (COVID-19) Pandemic: From Diagnosis to Treatment Strategies.

Authors:  Zhina Hadisi; Tavia Walsh; Seyed Mohammad Hossein Dabiri; Amir Seyfoori; David Hamdi; Bahram Mirani; Erik Pagan; Armando Jardim; Mohsen Akbari
Journal:  Adv Ther (Weinh)       Date:  2020-12-16

9.  Coronavirus Disease 2019 Triage Teams: Death by Numbers.

Authors:  Joel Zivot
Journal:  Crit Care Med       Date:  2020-08       Impact factor: 9.296

10.  Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 Mpro and spike protein: Drug repurposing approach.

Authors:  Mohammed A Abosheasha; Afnan H El-Gowily
Journal:  Drug Dev Res       Date:  2020-09-27       Impact factor: 5.004

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.